SCHEDULE: RA Capital Exits Day One Biopharma Stake

RA Capital Management and its affiliates have reported zero beneficial ownership in Day One Biopharmaceuticals, Inc. as of June 30, 2025.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed an Amendment No. 4 to Schedule 13G.
• As of June 30, 2025, all Reporting Persons reported 0.00 shares beneficially owned in Day One Biopharmaceuticals, Inc. Common Stock.
• The aggregate amount beneficially owned by each Reporting Person represents 0.0% of the class of securities.
• The filing indicates a complete divestment of their previously held stake in the company.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the complete divestment by a significant institutional investor, which typically signals a lack of confidence or a strategic shift away from the company.

Negatives

• A significant institutional investor, RA Capital Management, and its affiliates have fully divested their beneficial ownership in Day One Biopharmaceuticals, Inc.

Risks

• The complete divestment by a major institutional investor could signal a lack of confidence in the company's future prospects or a strategic reallocation of capital, potentially leading to negative market sentiment and share price pressure.

Industry Context

The divestment by a specialized healthcare investment fund like RA Capital Management from a biotechnology company such as Day One Biopharmaceuticals could be interpreted by the market as a re-evaluation of the company's potential within the competitive biotech landscape or a shift in investment strategy by the fund.

Stakeholder Impact

• Shareholders may experience negative sentiment and potential downward pressure on the stock price due to the exit of a major institutional investor.

Key Dates

Recommendation

The complete divestment by a prominent healthcare-focused institutional investor like RA Capital Management suggests a significant loss of confidence or a strategic decision to reallocate capital away from Day One Biopharmaceuticals. This action by a sophisticated investor often precedes or reflects underlying challenges or a less favorable outlook for the company, warranting a 'sell' recommendation for investors to consider exiting their positions.

Keywords

Day One Biopharmaceuticals, RA Capital Management, Schedule 13G, Beneficial Ownership, Divestment, Biotechnology, Institutional Investor